Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8965590 | Drug Discovery Today: Technologies | 2018 | 7 Pages |
Abstract
In this review we discuss achievements and current limitations of CRISPR/Cas9 genome editing in hematopoietic cells with special emphasis on its potential use in ex vivo gene therapy of monogenic blood disorders, HIV and cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Duran Sürün, Harald von Melchner, Frank Schnütgen,